| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.102.8.865 |
| P698 | PubMed publication ID | 10952954 |
| P2093 | author name string | Fukushima K | |
| Kangawa K | |||
| Satoh T | |||
| Kyotani S | |||
| Miyatake K | |||
| Nagaya N | |||
| Nakanishi N | |||
| Sakamaki F | |||
| Uematsu M | |||
| Nishikimi T | |||
| Okano Y | |||
| Kakishita M | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | primary pulmonary hypertension | Q18554794 |
| P304 | page(s) | 865-870 | |
| P577 | publication date | 2000-08-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension | |
| P478 | volume | 102 |
| Q36777766 | 2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension |
| Q36515926 | 4,4'-Methylenedianiline Alters Serotonergic Transport in a Novel, Sex-Specific Model of Pulmonary Arterial Hypertension in Rats. |
| Q61895118 | Algorithme diagnostique. Comment je raisonne devant une HTAP ? |
| Q37634323 | Ambrisentan for the treatment of pulmonary arterial hypertension |
| Q36839352 | Ambrisentan for the treatment of pulmonary arterial hypertension: improving outcomes |
| Q48118270 | Amino-terminal fragment of pro-brain natriuretic hormone identifies functional impairment and right ventricular overload in operated tetralogy of Fallot patients |
| Q36903518 | Amino-terminal pro-brain natriuretic peptide in children with latent rheumatic heart disease |
| Q37555352 | An advanced protocol-driven transition from parenteral prostanoids to inhaled trepostinil in pulmonary arterial hypertension |
| Q34919733 | An official American Thoracic Society Statement: pulmonary hypertension phenotypes |
| Q36704648 | An unexpected diagnosis in a dyspnoeic patient with primary Sjogren syndrome. |
| Q35153029 | Analysis of volatile compounds in exhaled breath condensate in patients with severe pulmonary arterial hypertension. |
| Q37019853 | Arterial pulmonary hypertension in noncardiac intensive care unit |
| Q38080707 | Assessment and treatment of right ventricular failure |
| Q93078834 | Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension |
| Q87420844 | Attenuated right ventricular energetics evaluated using ¹¹C-acetate PET in patients with pulmonary hypertension |
| Q46183109 | Autonomic nervous system involvement in pulmonary arterial hypertension. |
| Q35934084 | B-type natriuretic Peptide and the right heart |
| Q35968889 | B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension. |
| Q35115632 | B-type natriuretic peptide and mortality in extremely low birth weight infants with pulmonary hypertension: a retrospective cohort analysis |
| Q48434053 | B-type natriuretic peptide and weaning from mechanical ventilation |
| Q48237778 | B-type natriuretic peptide in cardiovascular disease |
| Q36466739 | B-type natriuretic peptide in the diagnosis of heart failure in the emergency department |
| Q48089433 | B-type natriuretic peptide levels in congenital heart disease |
| Q35911696 | B-type natriuretic peptide measurement in heart failure. |
| Q34516884 | B-type natriuretic peptide: prognostic marker in congenital diaphragmatic hernia |
| Q47848610 | Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry. |
| Q36411409 | Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension |
| Q33562258 | Bilirubin as a prognostic marker in patients with pulmonary arterial hypertension |
| Q38520683 | Biomarkers and prognostic indicators in pulmonary arterial hypertension |
| Q38251298 | Biomarkers in pulmonary arterial hypertension |
| Q64937061 | Biomarkers in the Diagnosis, Management, and Prognostication of Perioperative Right Ventricular Failure in Cardiac Surgery-Are We There Yet? |
| Q34717444 | Biomarkers of cardiac dysfunction and mortality from community-acquired pneumonia in adults |
| Q48220462 | Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath |
| Q48722884 | Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. |
| Q33573360 | Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent |
| Q37274564 | Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension |
| Q33150831 | Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism |
| Q33917277 | CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival |
| Q38603770 | Cardiac biomarkers in children with congenital heart disease |
| Q57475874 | Cardio-pulmonary MRI for detection of treatment response after a single BPA treatment session in CTEPH patients |
| Q36752821 | Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype |
| Q55285033 | Circulating Protein Biomarkers in Systemic Sclerosis Related Pulmonary Arterial Hypertension: A Review of Published Data. |
| Q92811812 | Circulating biomarkers in chronic thromboembolic pulmonary hypertension |
| Q34269881 | Circulating collagen biomarkers as indicators of disease severity in pulmonary arterial hypertension |
| Q40365615 | Clinical and functional characterisation of rheumatic mitral regurgitation in children and adolescents including the brain natriuretic peptide |
| Q34394040 | Clinical and haemodynamic evaluation of chronic thromboembolic pulmonary hypertension patients scheduled for pulmonary thromboendarterectomy: Is schistosomiasis hypertension an important confounding factor? |
| Q39386200 | Clinical significance of elevated B-type natriuretic peptide in patients with acute lung injury with or without right ventricular dilatation: an observational cohort study |
| Q90291712 | Comorbidity in idiopathic pulmonary fibrosis - what can biomarkers tell us? |
| Q55465394 | Comparison of Brain Natriuretic Peptide Levels to Simultaneously Obtained Right Heart Hemodynamics in Stable Outpatients with Pulmonary Arterial Hypertension. |
| Q51693204 | Current therapeutic approaches to pulmonary arterial hypertension. |
| Q89675115 | Demographic and clinical characteristics of pulmonary arterial hypertension caused by schistosomiasis are indistinguishable from other etiologies |
| Q84970094 | Determinants of the reduction in B‐type natriuretic peptide after mitral valve replacement in patients with rheumatic mitral stenosis |
| Q55001904 | Diagnosis, Evaluation and Treatment of Pulmonary Arterial Hypertension in Children. |
| Q34321315 | Differential prognostic utility of NTproBNP and Cystatin C in patients with acute exacerbation of chronic pulmonary disease |
| Q37016860 | Diminazene aceturate improves autonomic modulation in pulmonary hypertension |
| Q38271027 | Early detection of pulmonary arterial hypertension |
| Q52643350 | Effect of 6-min Walk Test on pro-BNP Levels in Patients with Pulmonary Arterial Hypertension. |
| Q42359702 | Effect of iloprost on biomarkers in patients with congenital heart disease-pulmonary arterial hypertension |
| Q57294005 | Effects of Pulmonary Hypertension and Right Ventricular Function in Short and Long-Term Kidney Function |
| Q48595800 | Effects of exercise training on pathological cardiac hypertrophy related gene expression and apoptosis |
| Q36287760 | Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension. |
| Q28085007 | Emerging Concepts in the Molecular Basis of Pulmonary Arterial Hypertension: Part II: Neurohormonal Signaling Contributes to the Pulmonary Vascular and Right Ventricular Pathophenotype of Pulmonary Arterial Hypertension |
| Q37235599 | Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma |
| Q35053507 | Evaluation of circulating proteins and hemodynamics towards predicting mortality in children with pulmonary arterial hypertension |
| Q43119833 | Evidence-based management of right heart failure: a systematic review of an empiric field |
| Q37784575 | Factors that prognosticate mortality in idiopathic pulmonary arterial hypertension: A systematic review of the literature |
| Q33788434 | Follow-up tricuspid annular plane systolic excursion predicts survival in pulmonary arterial hypertension |
| Q38112045 | Genomics and proteomics of pulmonary vascular disease |
| Q87292685 | Guidelines for the management of pulmonary hypertension patients |
| Q61895125 | Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar |
| Q92925812 | Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations |
| Q30483582 | Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology |
| Q44433579 | Hemodynamic and Hormonal Effects of Beraprost Sodium, an Orally Active Prostacyclin Analogue, in Patients With Secondary Precapillary Pulmonary Hypertension |
| Q35758718 | High levels of serum lactate dehydrogenase correlate with the severity and mortality of idiopathic pulmonary arterial hypertension |
| Q40730769 | Imaging right ventricular function to predict outcome in pulmonary arterial hypertension |
| Q37343794 | Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension |
| Q36721421 | Improvement of Right Ventricular Function in Pulmonary Arterial Hypertension with Disease-Specific Therapy - A Clinical Observational Study |
| Q48363961 | Interdependence of right ventricular systolic function and left ventricular filling and its association with outcome for patients with pulmonary hypertension |
| Q39192390 | Intravenous fasudil improves in-hospital mortality of patients with right heart failure in severe pulmonary hypertension. |
| Q28383488 | Lack of association between chronic exposure to biomass fuel smoke and markers of right ventricular pressure overload at high altitude |
| Q35412493 | Log-transformation improves the prognostic value of serial NT-proBNP levels in apparently stable pulmonary arterial hypertension |
| Q41669738 | Long-Term Survival of Patients with Pulmonary Arterial Hypertension at a Single Center in Taiwan |
| Q37378673 | Long-term efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension |
| Q36112957 | Management of heart failure with pulmonary hypertension |
| Q64064854 | Mitochondrial function remains impaired in the hypertrophied right ventricle of pulmonary hypertensive rats following short duration metoprolol treatment |
| Q64264437 | N-Terminal Pro-B-Type Natriuretic Peptide as a Biomarker of Bronchopulmonary Dysplasia or Death in Preterm Infants: A Retrospective Cohort Analysis |
| Q47986889 | N-terminal brain natriuretic peptide as a diagnostic test in cirrhotic patients with pulmonary arterial hypertension |
| Q36987869 | N-terminal pro B type natriuretic peptide in high cardiovascular-risk patients for noncardiac surgery: What is the current prognostic evidence? |
| Q46801429 | N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension |
| Q57051327 | NLRC3: A Novel Noninvasive Biomarker for Pulmonary Hypertension Diagnosis |
| Q57914127 | NT-proBNP Provides Incremental Prognostic Information in Cardiac Outpatients With and Without Echocardiographic Findings |
| Q42932903 | NT-proBNP correlated with strain and strain rate imaging of the right ventricle before and after transcatheter closure of atrial septal defects |
| Q38288274 | Natriuretic hormones in brain function |
| Q36983817 | Natriuretic peptides in cardiovascular diseases. |
| Q48541358 | Natriuretic peptides in the diagnosis of heart disease--first amongst equals? |
| Q37399526 | Natriuretic peptides in the management of aortic stenosis |
| Q34412447 | Nicorandil prevents right ventricular remodeling by inhibiting apoptosis and lowering pressure overload in rats with pulmonary arterial hypertension |
| Q35165691 | Non-congenital heart disease associated pediatric pulmonary arterial hypertension |
| Q37973537 | Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with Updated Commentary of the Cologne Consensus Conference 2011. |
| Q80651521 | Non-invasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis |
| Q26738666 | Novel biomarkers for pulmonary arterial hypertension |
| Q36619235 | Novel therapeutic approaches to preserve the right ventricle |
| Q35198572 | One-year prognosis and the role of brain natriuretic peptide levels in patients with chronic cor pulmonale |
| Q27023074 | Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course |
| Q35579856 | Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension |
| Q33168056 | Pericardial effusion is correlated with clinical outcome after pulmonary artery denervation for pulmonary arterial hypertension |
| Q40303684 | Pim-1: A new biomarker in pulmonary arterial hypertension |
| Q48181927 | Plasma Concentrations of Aminoterminal Pro Atrial Natriuretic Peptide and Aminoterminal Pro Brain Natriuretic Peptide in Healthy Neonates: Marked and Rapid Increase After Birth |
| Q35609802 | Plasma ProBNP Is Not a Specific Marker for Transient Myocardial Ischemia |
| Q42082434 | Plasma atrial natriuretic peptide and N-terminal pro B-type natriuretic peptide concentrations in dogs with right-sided congestive heart failure |
| Q36408867 | Plasma brain natriuretic peptide as a biomarker for haemodynamic outcome and mortality following pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension |
| Q48548279 | Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy |
| Q88796809 | Plasma miR-451 with echocardiography serves as a diagnostic reference for pulmonary hypertension |
| Q87454549 | Plasma soluble ST2 levels correlate with disease severity and predict clinical worsening in patients with pulmonary arterial hypertension |
| Q37677425 | Platelets from pulmonary hypertension patients show increased mitochondrial reserve capacity |
| Q83232565 | Portopulmonary hypertension |
| Q55081723 | Predictors of poor outcome in patients with pulmonary arterial hypertension: A single center study. |
| Q37081642 | Prevalence of Sodium and Fluid Restriction Recommendations for Patients with Pulmonary Hypertension |
| Q48089853 | Pro-brain natriuretic peptide as marker of cardiovascular or pulmonary causes of dyspnea in patients with terminal parenchymal lung disease |
| Q44394229 | Prognostic value of high plasma brain natriuretic peptide concentrations in very elderly persons |
| Q40013053 | Prognostic value of multiple biomarkers for cardiovascular mortality in adult congenital heart disease: comparisons of single-/two-ventricle physiology, and systemic morphologically right/left ventricles |
| Q30248871 | Pulmonary Hypertension in Children |
| Q34197167 | Pulmonary arterial hypertension in Saudi Arabia: Patients' clinical and physiological characteristics and hemodynamic parameters. A single center experience. |
| Q38621458 | Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial |
| Q35732584 | Pulmonary arterial hypertension: advances in pathophysiology and management |
| Q26825432 | Pulmonary hypertension survival effects and treatment options in cystic fibrosis |
| Q36834159 | Pulmonary hypertension: current diagnosis and treatment |
| Q35559191 | Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review |
| Q36075721 | QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension |
| Q37627314 | Randomised controlled trial examining the effect of an outpatient exercise training programme on haemodynamics and cardiac MR parameters of right ventricular function in patients with pulmonary arterial hypertension: the ExPAH study protocol. |
| Q44619356 | Repeated inhalation of adrenomedullin ameliorates pulmonary hypertension and survival in monocrotaline rats |
| Q37133796 | Reproducibility of intracardiac and transpulmonary biomarkers in the evaluation of pulmonary hypertension |
| Q37796685 | Right Ventricular Failure: A Novel Era of Targeted Therapy |
| Q47600093 | Right Ventricular Tissue Doppler Myocardial Performance Index in Children with Pulmonary Hypertension: Relation to Invasive Hemodynamics |
| Q40801700 | Right atrial emptying fraction non-invasively predicts mortality in pulmonary hypertension. |
| Q47561482 | Right atrial mechanics provide useful insight in pediatric pulmonary hypertension. |
| Q37907134 | Right side of heart failure |
| Q27318422 | Right ventricular adaptation and failure in pulmonary arterial hypertension |
| Q91274440 | Role of Pro-Brain Natriuretic Peptide Serum Concentration in the Detection of Pulmonary Hypertension in Patients With End-Stage Lung Diseases Referred for Lung Transplantation |
| Q33589653 | SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. |
| Q33965859 | Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertension |
| Q35898607 | Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin |
| Q33965904 | Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates |
| Q44758267 | Selective or nonselective endothelin receptor blockade in pulmonary arterial hypertension |
| Q36204005 | Serum Caveolin-1 as a Novel Biomarker in Idiopathic Pulmonary Artery Hypertension |
| Q36150934 | Severity of systemic sclerosis-associated pulmonary arterial hypertension in African Americans |
| Q33806163 | Short-term improvement in pulmonary hemodynamics is strongly predictive of long-term survival in patients with pulmonary arterial hypertension |
| Q40547439 | Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension |
| Q42785892 | Sildenafil and steroid therapy effectively improved POEMS syndrome-associated pulmonary arterial hypertension |
| Q34436782 | Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension |
| Q50887648 | Surgical strategy for severe aortic hypoplasia and aortic stenosis with ventricular septal defect and normal left ventricle. |
| Q35792872 | Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy |
| Q89598899 | The Right Ventricle-You May Forget it, but It Will Not Forget You |
| Q37196639 | The Yin and Yang of dyspnea in the emergency department: heart failure or COPD? |
| Q81360290 | The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients |
| Q37703738 | The heart as an endocrine organ. |
| Q37125318 | The management of pulmonary hypertension in children |
| Q36192931 | The neurohormonal axis and biochemical markers of heart failure |
| Q92133639 | The practical management of fluid retention in adults with right heart failure due to pulmonary arterial hypertension |
| Q34561996 | The proposed role of plasma NT pro-brain natriuretic peptide in assessing cardiac remodelling in hypertensive African subjects |
| Q48396557 | The ratio of the atrial areas reflects the clinical status of patients with pulmonary arterial hypertension |
| Q60363935 | Therapie der pulmonalarteriellen Hypertonie |
| Q37996827 | Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension |
| Q64890066 | Transection of the cervical sympathetic trunk inhibits the progression of pulmonary arterial hypertension via ERK-1/2 Signalling. |
| Q55154867 | Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study. |
| Q26851767 | Treatment goals of pulmonary hypertension |
| Q33156379 | Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial |
| Q28081276 | Treatment-related biomarkers in pulmonary hypertension |
| Q34609902 | Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry |
| Q42850835 | Utility of Echocardiography Versus BNP Level for the Prediction of Pulmonary Arterial Pressure in Patients With Pulmonary Arterial Hypertension |
| Q34558277 | Utility of NT-proBNP for identifying LV failure in patients with acute exacerbation of chronic bronchitis |
| Q59811485 | Utility of the amplitude of RV1+SV5/6 in assessment of pulmonary hypertension |
| Q89565553 | Volume Management in Pulmonary Arterial Hypertension Patients: An Expert Pulmonary Hypertension Clinician Perspective |
| Q40706456 | Whipple's disease-associated pulmonary hypertension with positive vasodilator response despite severe hemodynamic derangements |
| Q53745953 | [Biological markers. Utility in the management of patients with pulmonary hypertension]. |
| Q81522982 | [Biomarkers as prognostic factors in pulmonary arterial hypertension. Rationale and study design] |
| Q84204323 | [Diagnostics in pulmonary hypertension] |
| Q46809537 | [Pulmonary arterial hypertension]. |
| Q84790969 | [Treatment goals in pulmonary arterial hypertension] |
Search more.